Ping An CSI Medicine and Medical Device Innovation ETF

Optimization of Innovative Drug Medical Insurance Mechanism and Revival of Financing Drive Up Industry Sentiment

ZLAB

09688

159570

159929

589720

516820

510660

Hong Kong's innovative drug sector continues to experience a downturn, with Zai Labdropping over 6% and Jiangsu Hengrui Medicinefalling more than 4%. According to Jin10, other companies such as CSPC Pharmaceutical Groupand WuXi AppTecalso saw declines.

CoinLive

Zai Lab

ZAI LAB

China Universal CNI HK Connect Innovative Drugs Industry ETF

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

Bosera Hang Seng SCHK Innovative Drug Select ETF

Huaan Hang Seng Biotech ETF

Minsheng Royal CSI Biotechnology Theme ETF

China Universal 800 Health Care ETF

Guotai SSE STAR Brand Name Drug ETF

Hwabao WP CSI Pharmaceuticals ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

E Fund Hang Seng SCHK Innovative Drug ETF

HENGRUI PHARMA

CSPC PHARMA

WUXI APPTEC

WuXi AppTec

STOCKS | Hong Kong's Innovative Drug Sector Declines

00945

159837

516500

159849

Manulife Singapore will launch the Shield™ multi-cancer detection test in May 2026 through its partnership with Guardant Health, becoming the first in Singapore to offer this blood test for multiple cancers. This initiative supports preventive healthcare, addressing the rising demand for early cancer detection. The Shield™ test has received Breakthrough Device Designation from the FDA and was recognized as Oncology Product Innovation of the Year. Manulife aims to empower customers in managing their health and finances.

Singapore Business Review

Guardant Health

MANULIFE-S

Manulife Financial

Ark Genomic Revolution ETF

E Fund CSI Biotechnology Theme ETF

VanEck Biotech ETF

ChinaAMC CSI Biotechnology Theme ETF

Hwabao WP CSI Medical Service ETF

Direxion S&P Biotech Bull 3X

China Merchants CSI Biotechnology Theme ETF

Direxion S&P Biotech Bear 3X

Manulife Singapore to offer multi-cancer blood test starting May

The National Kidney Foundation (NKF) has invested in Biohope, a biotechnology firm focused on personalized medicine for kidney transplantation. This investment aims to support Biohope's clinical validation studies and regulatory approval for its Immunobiogram® platform, which tailors immunosuppressive therapy to individual patients. The technology seeks to reduce complications and improve graft survival for kidney transplant recipients, addressing the urgent need for personalized post-transplant care. NKF's Innovation Fund, launched in 2021, supports innovative kidney therapies to enhance patient outcomes.

prnewswire

Health Care Select Sector SPDR

First Trust NYSE Arca Biotech Index Fd

iShares Global Healthcare

VG Health

Invesco Biotechnology & Genome ETF

Proshares UltraShort Nasdaq Biotech

SPDR S&P Biotech

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

Invesco Nasdaq Biotechnology ETF

iShares US Pharma

ALPS Medical Breakthrough

01:00 ETNational Kidney Foundation Innovation Fund Invests in Biohope to Advance Personalized Medicine in Kidney Transplantation

588130

520880

159615

560600

512290

159892

SBP GROUPannounced preclinical data for its innovative drug TQF6422 at the 2026 European Congress on Obesity. TQF6422, a fully human monoclonal antibody targeting ActRII A/B, promotes muscle growth and fat reduction. Its in vitro activity exceeds comparable products by over 10 times. In combination with semaglutide, TQF6422 showed significant synergistic effects, increasing fat reduction by 1.5 to 2 times in an obese monkey model, with fat loss comprising 93% of total weight loss.

AASTOCKS News

ChinaAMC SSE STAR Biology and Medicine ETF

Penghua SSE STAR Biology and Medicine ETF

Tianhong CNI BIOMEDICINE ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

ICBCCS SSE STAR Biology and Medicine ETF

China Southern Hang Seng Biotech ETF(QDII)

Founder Fubon CSI Medicine and Medical Device Innovation ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

E Fund CSI 300 Health Care ETF

Yinhua CSI Innovative Drugs Industry ETF

Guotai CSI Bio-medicine ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

SBP GROUP

SBP GROUP  Announces Preclinical Data of Innovative Drug TQF6422 at European Congress on Obesity

Ab&B Bio-Tech CO., LTD. has begun Phase I and II trials for its recombinant RSV vaccine after receiving approval from China's National Medical Products Administration. The vaccine targets respiratory syncytial virus, crucial for vulnerable populations in China. Despite promising preclinical results, trading of the company's shares remains suspended since April 1, 2026, and there is no guarantee the vaccine will reach the market. Ab&B Bio-Tech focuses on innovative vaccines and has a diverse pipeline, including influenza and rabies vaccines.

Tip Ranks

Bosera Hang Seng Health Care ETF(QDII)

AB&B BIO-TECH-B

Ab&B Bio-Tech Starts Early-Stage Trials for High-Yield RSV Vaccine as Trading Remains Suspended

HBM Holdings Ltd. announced that its independent non-executive director, Dr. Xiaoping Ye, is under investigation by the China Securities Regulatory Commission for alleged information disclosure violations. The company stated that Dr. Ye does not engage in daily management and will cooperate with regulators. HBM's operations are reported to be normal, with no expected impact from the probe. Shareholders are advised to exercise caution during the inquiry. The latest analyst rating for HBM stock is a Buy, with a price target of HK$17.00.

HBM HOLDINGS-B

Tigermed

TIGERMED

HBM Holdings Says Director Probed by CSRC, Sees No Impact on Operations

A new clinical study published in Nature Communications highlights the effects of Efsubaglutide Alfa, a GLP-1 receptor agonist, on glycaemic control and β-cell function in adults with type 2 diabetes inadequately controlled on metformin. The SUPER 2 trial demonstrated significant improvements in HbA1c and other glycaemic measures, with a safety profile consistent with the GLP-1 class. The findings suggest that Efsubaglutide Alfa may also improve β-cell function, indicating potential long-term benefits beyond glycaemic control. Innogen Pharmaceuticals led the study, emphasizing the importance of mechanistic insights in developing therapies for metabolic diseases.

Penghua CSI HK Connect Health Care Composite ETF

BlackRock, Inc.

INNOGEN-B

23:47 ETNew Nature Communications Publication Highlights Efsubaglutide Alfa's Effects on Glycaemia and β-Cell Function

Kane Biotech Presents Data To Global Wound Care Community at WCET®–NSWOCC® 2026 Joint Congress | KNBIF Stock News

StockTitan

Kane Biotech Presents Data To Global Wound Care Community at WCET®–NSWOCC® 2026 Joint Congress | KNBIF Stock News

300347

Shanghai-based Immunocan has successfully closed a RMB250 million Series A funding round, led by Vivo Capital, with participation from Gold Mine Multi Family Office and existing investors like Kingray Capital and TigerYeah Capital. The funds will be utilized to enhance its gene-edited animal platforms, commercialize its fully human antibody rabbit platform, develop an AI-driven antibody drug screening platform, and expand its team. Founded in 2020, Immunocan specializes in antibody discovery using gene-editing technologies and collaborates with various pharmaceutical companies globally.

TechNode

ChinaAMC CSI All Share Health Care Devices ETF

China Universal NASDAQ Biotechnology Technology ETF(QDII)

Antibody discovery platform Immunocan closes RMB250 million Series A

Innovent Biologics, Inc. will present clinical and preclinical results of mazdutide and its next-generation obesity and metabolic pipeline at the 2026 ADA Scientific Sessions in New Orleans from June 5-8, 2026. Key presentations include studies on mazdutide's efficacy in adults and adolescents with obesity and type 2 diabetes, highlighting its profile as a GCG/GLP-1 dual receptor agonist. The pipeline also features innovative oral GLP-1 receptor agonists and an amylin analog aimed at addressing obesity-related challenges. This event marks a significant step for Innovent in establishing leadership in obesity and metabolic disease treatment.

Unusual Whales

Guotai CSI Hugangshen Innovative Drugs Industry ETF

INNOVENT BIO

Innovent to Present Multiple Clinical and Preclinical Results of Mazdutide and Next-Generation Obesity & Metabolic Pipeline at the 2026 ADA Scientific Sessions

Ping An CSI Medicine and Medical Device Innovation ETF(516820.SH)

STOCKS | Hong Kong's Innovative Drug Sector Declines

Manulife Singapore to offer multi-cancer blood test starting May

01:00 ETNational Kidney Foundation Innovation Fund Invests in Biohope to Advance Personalized Medicine in Kidney Transplantation

SBP GROUP Announces Preclinical Data of Innovative Drug TQF6422 at European Congress on Obesity

Ab&B Bio-Tech Starts Early-Stage Trials for High-Yield RSV Vaccine as Trading Remains Suspended

HBM Holdings Says Director Probed by CSRC, Sees No Impact on Operations

23:47 ETNew Nature Communications Publication Highlights Efsubaglutide Alfa's Effects on Glycaemia and β-Cell Function

Kane Biotech Presents Data To Global Wound Care Community at WCET®–NSWOCC® 2026 Joint Congress | KNBIF Stock News

Antibody discovery platform Immunocan closes RMB250 million Series A

Innovent to Present Multiple Clinical and Preclinical Results of Mazdutide and Next-Generation Obesity & Metabolic Pipeline at the 2026 ADA Scientific Sessions